Accessibility Menu

What Sent DaVita Stock Soaring On Tuesday?

The market now seems to realize it may have misjudged this company's future.

By James Brumley Feb 3, 2026 at 12:18PM EST

Key Points

  • Shares of kidney dialysis treatment company DaVita understandably struggled in 2025.
  • Its most recent quarterly report and guidance for the year ahead, however, were both better than anticipated.
  • While still far from being a growth name, this stock is undervalued at its present price.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.